Robert Mashal

Director Robert Mashal buys 25,000 shares of NUVB at $4.73; all 4 prior same-ticker purchases show 90d gains, currently -51.2% from 52-week high

Director Robert Mashal purchased 25,000 shares at $4.73, increasing his holdings to 225,000 shares (+12.5% increase). His track record at NUVB is notable: all 4 prior open-market purchases at this ticker showed positive 90-day returns (ranging from +16.8% to +29.4%), indicating consistent timing on the buy side. The current price of $4.76 sits -51.2% from the 52-week high of $9.75, meaning the stock has declined substantially from recent peaks. Fundamentally, the company posted $83.2M in revenue and $5.4M net income in its latest quarter, alongside +699.0% annual revenue growth, though it remains unprofitable on a full-year basis, creating a contrast between strong top-line momentum and unresolved profitability concerns.

Director Mashal Robert doubled NUVB holdings to 200,000 shares via 2 purchases totaling 100,000 shares for $166,985.16 at $1.67.

Mashal Robert, a director at Nuvation Bio, executed 2 separate open-market purchases totaling 100,000 shares for $166,985.16, doubling his equity position from 100,000 to 200,000 shares on 2025-04-01. The purchases occurred at $1.67 per share, a price 0.6% above the current market price of $1.66 and positioned in the lower half of the 52-week range ($1.66–$3.83). His prior two purchases at NUVB on 2024-10-08 each yielded positive 90-day returns (+29.4% and +29.1% respectively), establishing a pattern of well-timed entry points at this ticker. However, the company remains unprofitable with a net loss of $-41,210,000.00 in its most recent fiscal year and minimal revenue of $727,000.00, creating a tension between the insider's accumulation pattern and the underlying financial stress. The 30-day and 90-day price declines (-8.8% and -42.6% from recent peaks) place this transaction in a depressed price window, though without scheduled trading plan disclosure, the timing rationale remains opaque.

Director Mashal Robert purchases 100,000 shares of NUVB at $2.20 (blended avg); current price $2.01, stock down 49.4% from 52-week high.

Mashal Robert, a director, acquired 100,000 shares across 2 separate transactions on 2024-10-08, paying a blended average price of $2.20 per share, establishing a new 100,000-share position from zero prior holdings. The timing occurs as the stock has declined 49.4% from its 52-week high of $3.97 and is currently trading at $2.01, below the purchase price. The company faces significant headwinds: latest quarterly revenue was $1.4M, full-year net income was negative, and the most recent quarterly loss was $-462.5M, indicating substantial burn against a $501.0M market cap. This large, new acquisition by a director warrants examination of whether it represents conviction in a recovery scenario or reflects other motivations, given the company's current unprofitability and ongoing capital depletion.